Compare AbbVie Inc (ABBV) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs QUALCOMM, Inc. — how do they compare? AbbVie Inc trades at $249.02 (market cap $438.19B), while QUALCOMM, Inc. trades at $162.84 (market cap $170.28B). The key difference: AbbVie Inc is far larger — about 2.6× QUALCOMM, Inc.'s market cap, and AbbVie Inc pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| ABBV | QCOM | |
|---|---|---|
Market Cap | $438.19B | $170.28B |
Sector | Health | Technology |
52-Week High | $263.58 | $251.10 |
52-Week Low | $197.38 | $124.07 |
Enterprise Value | $502.45B | $177.24B |
Dividend Yield | 2.79% | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $249.94, up 1.59% today, with a bullish technical signal and strong analyst consensus. Recent earnings beats (Q4 2025 to Q2 2026) and a 70.73% buy rating from analysts highlight confidence. Revenue grew to $61.16B in 2025, though net margin dipped to 6.9%, while Skyrizi and Rinvoq drive growth post-Humira patent expiry. A dividend of $1.73 is scheduled for August 2026, supporting income appeal.
Outlook is positive with a $281.33 price target, but risks include high P/E of 70.05, patent cliffs in the 2030s, and regulatory lawsuits. Institutional buying and robust pipeline innovations like ELAHERE® in ovarian cancer offer upside, yet valuation and competitive pressures warrant caution for growth sustainability.
Qualcomm (QCOM) trades at $167.86, up 4.66% with strong recent earnings performance despite a Q2 2026 miss. The stock shows bullish technical signals with solid fundamentals including $44.28B revenue and 21.01% net margin. Recent news highlights Qualcomm's AI and automotive diversification efforts, though competition from Nvidia's PC chip entry poses challenges. Analyst consensus targets $200.56 with 42.65% buy ratings.
Qualcomm presents a balanced opportunity with strong cash flow generation and strategic diversification into AI/data centers offsetting smartphone market softness. Key risks include margin pressures and intensified competition. The current valuation at 19.18 P/E appears reasonable given growth initiatives, supporting a cautiously optimistic outlook for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
